Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: t
View:
• Male and Female subjects must be ≥18 and \<90 years of age;
• Able to understand and provide informed consent prior to study procedures
• Must be in good health
Locations
United States
Connecticut
Yale University PET Center
RECRUITING
New Haven
Contact Information
Primary
Shannan Henry
shannan.henry@yale.edu
+1 (203) 737-5278
Backup
Kayla Cottiers
kayla.cottiers@yale.edu
203-737-7496
Time Frame
Start Date: 2025-05-05
Estimated Completion Date: 2030-05-05
Participants
Target number of participants: 105
Treatments
Active_comparator: Healthy Control
n = 30 - up to three PET scanning sessions.
Experimental: Alzheimer's Disease (AD)
n = 15 - up to three PET scanning sessions.
Experimental: Mild Cognitive Impairment (MCI)
n = 15 - up to three PET scanning sessions.
Experimental: Multiple Sclerosis (MS)
n = 15 - up to three PET scanning sessions.
Experimental: Spinal Cord Injury (SCI)
n = 15 - up to three PET scanning sessions.
Experimental: Spinal radiculopathy (SR)
n = 15 - up to three PET scanning sessions.
Related Therapeutic Areas
Sponsors
Collaborators: National Institute for Biomedical Imaging and Bioengineering (NIBIB), National Institute on Aging (NIA)
Leads: Yale University